Volume 7, Issue 4 November 2013
November 2013 (Volume 7, Issue 4)
Drug Safety Update is essential reading for all healthcare professionals, bringing you the very latest information and advice to support the safer use of medicines.
Different antiepileptic drugs (AEDs) vary considerably in their characteristics, which influences the risk of whether switching between different manufacturers’ products of a particular drug may cause adverse effects or loss of seizure control. AEDs have been divided into three risk-based categories to help healthcare professionals decide whether it is necessary to maintain continuity of supply of a specific manufacturer’s product
There is new evidence on neurodevelopmental delay in children following maternal use of sodium valproate. A European review is underway to evaluate all currently available evidence on the association between fetal valproate exposure and neurodevelopmental delay or autism spectrum disorderHealthcare professionals are reminded that sodium valproate should not be used during pregnancy and in women of childbearing potential unless clearly necessary.
The use of short-acting β2 agonists (SABAs) for tocolysis in premature labour has been restricted to 48 hours’ maximum parenteral use under specialist supervision, after a European safety review. Oral SABAs should not be used in any obstetric indication.
Cabazitaxel is supplied as a vial of concentrate and a vial of solvent. The concentrate must first be diluted with the solvent supplied before adding to the infusion solution
It is essential that the entire contents of the solvent vial is added to the concentrate vial to produce a concentrate-solvent mixture with the intended concentration of 10 mg/mL cabazitaxel
Pharmacies should review worksheets used in the preparation of cabazitaxel to ensure that they inform pharmacy staff to add the entire contents of the solvent vial to the concentrate vial
Although the risk of neuropsychiatric side effects with mefloquine is well-established, a recent review of the prescribing information has led to strengthened warnings and new measures to help minimise risks.
To minimise the risk of these adverse reactions, mefloquine must not be used for chemoprophylaxis in patients with active or a history of psychiatric disturbances such as depression, anxiety disorders, schizophrenia, or other psychiatric disorders.